Introduction 1
The pharmaceutical industry produces many new potential therapeutic 2 agents that have poor water solubility. Many of these hydrophobic agents 3 show promising results during in vitro studies, when administered dissolved 4 in solvents like DMSO. However, when undergoing pre-clinical testing, the 5 hydrophobicity of drugs often makes them difficult to deliver, resulting in re-6 duced bioavailability and efficacy. [1] . A multitude of different routes for hy- clude ultrasonication [10] and high pressure homogenisation [11, 12, 13, 14] , 18 resulting in nanodroplets below 300 nm in diameter. Such nanodroplets are 19 particularly relevant for drug delivery as they are able to achieve good pene-20 tration though small capillaries as well as uptake across tissue. [15] There are 21 several factors that influence the size of the nanodroplets within an emulsion.
22
For the specific case of high-pressure homogenisation, the production pressure Tween, [20] to the lipids. The homogenisation process began with a blending step using 131 the rotor-stator system Polytron PT1300 D (Kinematica AG, Switzerland).
132
Polytron blending of the sample was carried out at 12500 rpm for 10 min, into the water phase, and to dissolve big lipid agglomerates. This mixing step 220 was followed by high pressure homogenisation for 20 min in an Emulsiflex.
221
In this device, the crude emulsion was forced though a homogenising nozzle,
222
where it experienced great mechanical stress for a short time. which the LONDs would be exposed to in vivo. 
TEM imaging of LONDs

333
TEM was used to image LOND samples. Figure 6 shows the TEM images 
Conclusion
385
We have carried out a systematic study on the formation of lipid-stabilised 386 oil nanodroplets (LONDs) with a range of biocompatible oils, towards med-387 ical applications. LONDs are formed in a two-step process that includes
388
A c c e p t e d M a n u s c r i p t blending using a rotor-stator system and high pressure homogenisation. 408 M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t Figure 5 : a) Size change of squalane and triacetin LONDs over a six week period, stored at 4
• C, and measured using DLS. b) Size change of squalane and triacetin LONDs at 37
• over 2 h, as measured by DLS. Experimental points in both graphs were produced averaging three size measurements on the same sample. M a n u s c r i p t Figure 7 : CA4 tripropionin LONDs disrupt microtubules in vitro. SVR mouse endothelial cells were treated with CA4 tripropionin LONDs at a dose escalation range between 2 nM to 100 nM for 2h at 37
• C follwed by washing and fixing with 4% paraformaldehyde. Immunofluorescence staining of β-tubulin was carried out. Prolong Gold with DAPI was used to mount and visualise the nuclei. The results show at higher doses of 100 nM to 40 nM CA4 released from the LONDs causes complete microtubule disruption leading to a uniform fluorescence around the nuclei. Lower doses of 20 nM to 2 nM show a varying lengths of microtubule filaments. Untreated cells were used as control where normal microtubules can be seen. Scale bar 50 µm. M a n u s c r i p t M a n u s c r i p t 
